<DOC>
	<DOCNO>NCT00012038</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I/II trial study effectiveness irofulven treat patient progressive recurrent astrocytoma , oligodendroglioma , glioblastoma multiforme .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Progressive Recurrent Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) irofulven alone combined anticonvulsant know metabolized cytochrome P450 patient progressive recurrent high-grade anaplastic astrocytoma , anaplastic oligodendroglioma , glioblastoma multiforme . - Assess pharmacokinetics drug schedule determine effect P450-inducing anticonvulsant pharmacokinetics patient . - Determine response rate patient treat drug administer MTD . - Determine duration progression-free survival overall survival patient treated drug . - Determine toxic effect drug patient . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord concurrent use anticonvulsant drug induce cytochrome P450 ( yes v drug modest-induction drug ) . Patients receive irofulven IV 30 minute day 1-4 1-5 ( depend dose-escalation level ) . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient ( per stratum ) receive escalate dos irofulven maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue receive treatment irofulven recommend phase II dose . Patients follow 1 week every 2 month thereafter . PROJECTED ACCRUAL : Approximately 18 patient ( 9 per stratum ) accrue phase I portion study . Approximately 17-35 patient accrue phase II portion study within 6-12 month .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove malignant highgrade glioma progressive recurrent radiotherapy and/or chemotherapy Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Prior lowgrade glioma progress highgrade glioma radiotherapy and/or chemotherapy allow Measurable disease MRI CT scan PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious concurrent infection medical illness would preclude study therapy No prior malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix breast Mini mental score least 15 PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 2 prior chemotherapy regimen At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) recover Endocrine therapy : Maintained stable corticosteroid regimen least 5 day study Radiotherapy : See Disease Characteristics At least 3 month since prior radiotherapy recover Surgery : Recovered prior surgery Other : No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>